Surgical and reconstructive outcomes in primary venous leiomyosarcoma.


Journal

Journal of vascular surgery. Venous and lymphatic disorders
ISSN: 2213-3348
Titre abrégé: J Vasc Surg Venous Lymphat Disord
Pays: United States
ID NLM: 101607771

Informations de publication

Date de publication:
07 2022
Historique:
received: 21 02 2020
accepted: 22 07 2021
pubmed: 6 8 2021
medline: 22 6 2022
entrez: 5 8 2021
Statut: ppublish

Résumé

Primary venous leiomyosarcomas (PVL) are rare and pose challenges in surgical management. This study evaluates the clinical outcomes and identifies predictors of survival in our surgical series of PVL. A retrospective review was performed of patients who had resection of PVL at three centers between 1990 and 2018. Patient demographics, comorbidities, intraoperative data, survival, and graft-related outcomes were recorded. Survival analysis was performed using Kaplan-Meier curves and Cox proportional hazards regression. Seventy patients with a diagnosis of PVL were identified between 1990 and 2018. Fifty-four patients (77%) had PVL of the inferior vena cava (IVC) and 16 (23%) had peripheral PVL. The mean follow-up for the series was 55.0 months (range, 1-217 months). Fifty-one patients (96%) with IVC-PVL needed caval reconstruction and 3 (4%) had resection only. There were no deaths within 30 days of surgery. Five patients (9%) required early reintervention including one (2%) IVC stent. Sixteen peripheral PVL were identified. Eight patients (50%) had venous reconstructions performed and 8 (50%) had the vein resected without reconstruction. There were no deaths within 30 days. Five-year survival was 57.5% for IVC-PVL and 70.0% for peripheral PVL. Kaplan-Meier survival analysis for IVC and peripheral PVL revealed no difference in overall survival (P = .624) at 5 years. PVL is a rare and aggressive disease even with surgical resection. We found no difference in survival between IVC and peripheral lesions, suggesting that aggressive management is warranted for PVL of any origin. Management of PVL requires a multidisciplinary approach to provide patients with the best long-term outcomes.

Identifiants

pubmed: 34352417
pii: S2213-333X(21)00393-0
doi: 10.1016/j.jvsv.2021.07.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

901-907

Informations de copyright

Copyright © 2021 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

William W Sheaffer (WW)

Division of Vascular Surgery, Mayo Clinic Arizona, Phoenix, Ariz. Electronic address: Sheaffer.william@mayo.edu.

Victor J Davila (VJ)

Division of Vascular Surgery, Mayo Clinic Arizona, Phoenix, Ariz.

Bernardo C Mendes (BC)

Division of Vascular Surgery, Mayo Clinic Rochester, Rochester, Minn.

Andrew J Meltzer (AJ)

Division of Vascular Surgery, Mayo Clinic Arizona, Phoenix, Ariz.

William M Stone (WM)

Division of Vascular Surgery, Mayo Clinic Arizona, Phoenix, Ariz.

Ina Y Soh (IY)

Division of Vascular Surgery, Mayo Clinic Arizona, Phoenix, Ariz.

Mark J Truty (MJ)

Department of General Surgery Subspecialties, Mayo Clinic Rochester, Rochester, Minn.

David M Nagorney (DM)

Department of General Surgery Subspecialties, Mayo Clinic Rochester, Rochester, Minn.

Samuel R Money (SR)

Division of Vascular and Endovascular Surgery, Ochnser Medical Center, New Orleans, La.

Thomas C Bower (TC)

Division of Vascular Surgery, Mayo Clinic Rochester, Rochester, Minn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH